ALGS vs ARWR vs HALO vs RCUS vs GILD

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -44. 6% for Aligos Therapeutics, Inc. (ALGS). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Arrowhead Pharmaceuticals, Inc. (ARWR) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 19. 8x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -99. 1% for Aligos Therapeutics, Inc. (ALGS). Over 10 years, the gap is even starker: ARWR returned +1253% versus ALGS's -98. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Aligos Therapeutics, Inc. 's 2. 11β — meaning ALGS is approximately 279% more volatile than HALO relative to the S&P 500. On balance sheet safety, Aligos Therapeutics, Inc. (ALGS) carries a lower debt/equity ratio of 10% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -44. 6% for Aligos Therapeutics, Inc. (ALGS). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -1106. 7% for Aligos Therapeutics, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -40. 2% for ALGS. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 1x forward P/E versus 15. 7x for Gilead Sciences, Inc. — 7. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RCUS: 21. 0% to $30. 00.

In this comparison, GILD (2.

4% yield) pays a dividend. ALGS, ARWR, HALO, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Gilead Sciences, Inc.

(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 4% yield). Aligos Therapeutics, Inc. (ALGS) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GILD: +87. 8%, ALGS: -98. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALGS is a small-cap quality compounder stock; ARWR is a mid-cap high-growth stock; HALO is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; GILD is a mid-cap quality compounder stock. GILD pays a dividend while ALGS, ARWR, HALO, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.